jzs-10884

Intralesional Injection of Measles, Mumps, and Rubella Vaccine in Molluscum Contagiosum Treatment: An Experimental Study

Sirwan Akram Karim1 & Darsim Mohammed Abdulla1*

1 Department of Dermatology, College of Medicine, University of Sulaimani, Sulaimani, Kurdistan Region, Iraq

  * Corresponding author’s E-mail: sirwankarim@univsul.edu.iq

Original: 02/08/2022                Revised: 26/08/2022                  Accepted: 29/08/2022                   Published online: 20/12/2022 

DOI Link: 

Abstract

Molluscum contagiosum (MC) is a common viral infection that affects the skin and the mucous membranes. Several studies have shown that intralesional Measles, Mumps, and Rubella (MMR) immunotherapy is beneficial for treating warts. There is very little information about the effectiveness of this treatment method in patients with MC. The study's objective was to assess whether patients with MC benefit from intralesional MMR vaccination. This experimental study was carried out on 20 patients of MC (11 men and 9 women) who visited Sulaimani Dermatology Teaching Center, who received a maximum of six doses of intralesional MMR vaccine with an interval of two weeks between sessions. Three kinds of therapy responses were identified; complete, partial, and no response. A number of side effects were recorded. The mean ± SD of the age, duration of the disease, and the number of skin lesions were 17.9 ±17.1 years, 5.1 ±2.2 months, and 10.4 ±7.9 lesions, respectively. Sixty-five percent of patients had complete clearance, 25% with partial clearance and 10% experienced no clearance. According to the examined variables, no significant difference was present in the frequency of the various treatment responses (p>0.05). The noticed side effects were temporary mild redness, edema, and pain at the site of injection. Recurrence was not seen in any of the patients who responded completely to the treatment. Although it seems that intralesional MMR immunotherapy was effective and safe in the treatment of the skin lesions due to MC. To further support the results of the current study, larger prospective studies that are placebo-controlled and have longer follow-ups are required.

Keywords: Intralesional immunotherapy, MMR, Intralesional injection, Molluscum contagiosum, Vaccine 

References

[1] Khattab, F.M. & Nasr, M.M. (2020). A comparative study of topical cantharidin and intralesional PPD to treat molluscum contagiosum. Journal of Dermatological Treatment. 31(8), 850-854.

[2] Na, C.H., Kim, D.J., Kim, M.S., Kim, J.K. & Shin, B.S. (2014). Successful treatment of molluscum contagiosum with intralesional immunotherapy by measles, mumps, and rubella vaccine: a report of two cases. Dermatologic Therapy. 27(6), 373-376.

[3] Peterson, A.R., Nash, E. & Anderson, B. (2019). Infectious disease in contact sports. Sports Health. 11(1), 47-58.

[4] Rosenberg, E.W. & Skinner Jr, R.B. (2006). Immunotherapy of alopecia areata with intralesional Candida antigen. Pediatric Dermatology. 23(3), 299-299.

[5] Gur, I. (2008). The epidemiology of Molluscum contagiosum in HIV-seropositive patients: a unique entity or insignificant finding? International journal of STD & AIDS. 19(8), 503-506.

[6] Leung, A.K., Barankin, B. & Hon, K.L. (2017). Molluscum contagiosum: an update. Recent Patents on Inflammation & Allergy Drug Discovery. 11(1), 22-31.

[7] Meza-Romero, R., Navarrete-Dechent, C. & Downey, C. (2019). Molluscum contagiosum: an update and review of new perspectives in etiology, diagnosis, and treatment. Clinical, Cosmetic and Investigational Dermatology. 12 (1),  373-381.

[8] Ruby, K.N., Perry, A.E. & Linos, K. (2018). Expanding the Morphologic Heterogeneity of Stromal Changes in Molluscum Contagiosum Infection. The American Journal of Dermatopathology. 40(12), 941-943.

[9] Rayala, B.Z. & Morrell, D.S. (2017). Common Skin Conditions in Children: Skin Infections. FP essentials. 453, 26-32.

[10] Hanson, D. & Diven, D.G. (2003). Molluscum contagiosum. Dermatology online journal. 9(2), 2-6.

[11] Badri, T. & Gandhi, G.R. (2022). Molluscum contagiosum. Treasure Island (FL): StatPearls Publishing.

[12] Enns, L.L. & Evans, M.S. (2011). Intralesional immunotherapy with Candida antigen for the treatment of molluscum contagiosum in children. Pediatric Dermatology. 28(3), 254-258.

[13] van der Wouden J.C., van der Sande R., Kruithof E.J., Sollie A., van Suijlekom‐Smit L.W. & Koning S.. (2017). Interventions for cutaneous molluscum contagiosum. Cochrane Database of Systematic Reviews.

[14] Scheinfeld, N. (2007). Treatment of molluscum contagiosum a brief review and discussion of a case successfully treated with adapelene. Dermatology Online Journal. 13(3), 15-20.

[15] Short, K.A., Fuller, L.C. & Higgins, E.M. (2006). Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology. 23(3), 279-281.

[16] Plotkin, S.A. (2001). Immunologic correlates of protection induced by vaccination. The Pediatric infectious disease journal. 20(1), 63-75.

[17] Horn, T.D., Johnson, S.M., Helm, R.M., Roberson & P.K. (2005). Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Archives of Dermatology. 141(5), 589-594.

[18] Rezai, M.S., Ghasempouri, H., Marzidareh, O.A., Cherati, J.Y. & Rokni, G.R. (2019). Intralesional injection of the Measles-Mumps-Rubella vaccine into resistant palmoplantar warts: A randomized controlled trial. Iranian Journal of Medical Sciences. 44(1), 10-17.

[19] Chauhan, P., Jindal, R. & Meena, D. (2021). Intralesional measles, mumps, and rubella vaccine immunotherapy in molluscum contagiosum: A retrospective observational study from a tertiary care center in north India. Dermatologic Therapy. 34(1), e14615.

[20] Nofal, A., Nofal, E., Yosef, A. & Nofal, H. (2015). Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach. International Journal of Dermatology. 54(6), 667-671.

[21] Mohta, A., Kushwaha, R.K., Gautam, U., Sharma, P., Nyati, A. & Jain, S.K. (2020). A comparative study of the efficacy and safety of intralesional measles, mumps, and rubella vaccine versus intralesional vitamin D3 for the treatment of warts in children. Pediatric Dermatology. 37(5), 853-859.

[22] Wells, A., Saikaly, S.K. & Schoch, J.J. (2020). Intralesional immunotherapy for molluscum contagiosum: a review. Dermatologic Therapy. 33(6), e14386.

[23] Nofal, A. & Nofal, E. (2010). Intralesional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. Journal of the European Academy of Dermatology and Venereology. 24(10), 1166-1170.

[24] Johnson, S.M., Roberson, P.K. & Horn, T.D. (2001). Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Archives of Dermatology. 137(4), 451-455.

[25] Shaldoum, D.R., Hassan, G.F., El Maadawy, E.H. & El‐Maghraby, G.M. (2020). Comparative clinical study of the efficacy of intralesional MMR vaccine vs intralesional vitamin D injection in treatment of warts. Journal of Cosmetic Dermatology. 19(8), 2033-2040.

[26] Mohamad, N.S., Badran, F. & Yakout, E. (2013). Evaluation of the efficacy of a combination-measles, mumps and rubella vaccine in the treatment of plantar warts. Our Dermatol Online. 4(4), 463-467.

View Full Article